A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Crenezumab (Primary) ; Crenezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ABBY
  • Sponsors Genentech
  • Most Recent Events

    • 16 Jul 2014 Results presented at the 2014 Alzheimers Association International Conference, as reported in an AC Immune media release
    • 16 Jul 2014 Primary endpoint has not been met. (Alzheimers disease assessment (change in Alzheimers Disease Assessment Scale Cognitive subscale [ADAS-Cog (12-item)] score between baseline and Week 73))
    • 16 Jul 2014 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top